Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Alessandra Pascucci"'
Autor:
Nicoletta Mancianti, Sergio Antonio Tripodi, Alessandra Pascucci, Marta Calatroni, Edoardo La Porta, Andrea Guarnieri, Guido Garosi
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 7, p 1828 (2024)
Introduction: The combination therapy of platinum and pembrolizumab looks like a promising treatment in advanced non-small-cell lung cancer. However, both platinum-based chemotherapy and pembrolizumab can lead to AKI. AKI can occur due to acute tubul
Externí odkaz:
https://doaj.org/article/fd9d138d7af04468bd731938cf29a265
Autor:
Gabriella Doddato, Floriana Valentino, Annarita Giliberti, Filomena Tiziana Papa, Rossella Tita, Lucia Pia Bruno, Sara Resciniti, Chiara Fallerini, Elisa Benetti, Maria Palmieri, Maria Antonietta Mencarelli, Alessandra Fabbiani, Mirella Bruttini, Alfredo Orrico, Margherita Baldassarri, Francesca Fava, Diego Lopergolo, Caterina Lo Rizzo, Vittoria Lamacchia, Sara Mannucci, Anna Maria Pinto, Aurora Currò, Virginia Mancini, Oncologic Multidisciplinary Team, Azienda Ospedaliera Universitaria Senese, Oncologic Multidisciplinary Team, Azienda Usl Toscana Sud Est, Francesca Mari, Alessandra Renieri, Francesca Ariani, Alessandro Neri, Donato Casella, Andrea Bernini, Stefania Marsili, Roberto Petrioli, Salvatora Tindara Miano, Alessandra Pascucci, Ignazio Martellucci, Monica Crociani, Marta Vannini, Federica Fantozzi, Andrea Stella, Alessia Carmela Tripodi, Angelamaria Giusti, Alfonso Fausto, Lucia Mantovani, Francesca Belardi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Hereditary Breast and Ovarian Cancer (HBOC) syndrome is a condition in which the risk of breast and ovarian cancer is higher than in the general population. The prevalent pathogenesis is attributable to inactivating variants of the BRCA1-2 highly pen
Externí odkaz:
https://doaj.org/article/ca4532e26c24440eb12237fb2fc7eb0a
Autor:
Andrea Spini, Rosa Gini, Pietro Rosellini, Allison Singier, Cristiana Bellan, Alessandra Pascucci, Lorenzo Leoncini, Clément Mathieu, Ignazio Martellucci, Folco Furiesi, Silvano Giorgi, Sandra Donnini, Giuseppe Roberto, Marina Ziche, Francesco Salvo
Publikováno v:
Cancers, Vol 13, Iss 23, p 6129 (2021)
(1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology
Externí odkaz:
https://doaj.org/article/ca286271290c4987a08ca1659bdff5e5
Autor:
Filippo Francini, Alessandra Pascucci, Edoardo Francini, Gianluca Bargagli, Raffaele Conca, Antonella Licchetta, Giandomenico Roviello, Ignazio Martellucci, Giorgio Chiriacò, Salvatora Tindara Miano, Giuseppe Marzocca, Antonio Manganelli, Roberto Ponchietti, Vinno Savelli, Roberto Petrioli
Publikováno v:
Prostate Cancer, Vol 2011 (2011)
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30
Externí odkaz:
https://doaj.org/article/a1065ac7a88d406a9d014508519fdb43
Autor:
Alessandra Pascucci
Publikováno v:
QUADERNI DI ECONOMIA DEL LAVORO. :21-48
Il presente articolo intende presentare, in modo sintetico, i risultati di un'indagine condotta da luglio 2011 a luglio 2012, sul progetto FIxO II destinato all'inserimento lavorativo dei dottori e dottorandi di ricerca. La presente ricerca nasce dal
Autor:
Roberto Petrioli, Alessandra Pascucci, Guido Francini, Loretta Paolelli, Edoardo Francini, Francesco Salvestrini, Antonio Manganelli
Publikováno v:
European Journal of Surgical Oncology (EJSO). 34:216-221
Aims Most patients with stage T3–T4 prostate cancer experience disease relapse despite radiation and/or hormonal therapy, and their management remains controversial. We investigated the feasibility of, and the pathological response induced by neoad
Autor:
Loretta Paolelli, Antonio Manganelli, Francesco Salvestrini, Giovanni De Rubertis, G. Barbanti, Alessandra Pascucci, Angela Sciandivasci, Roberto Petrioli, Guido Francini, Stefania Marsili, Edoardo Francini
Publikováno v:
Anti-Cancer Drugs. 18:817-820
The aim of this study was to evaluate the activity and toxicity of capecitabine as third-line treatment in patients with advanced renal cell carcinoma for whom immunotherapy had failed. Twenty-one patients with metastatic clear renal cell carcinoma w
Autor:
Roberto Petrioli, Gianluca Bargagli, Alessandra Pascucci, Salvatora Tindara Miano, Filippo Francini, Grazia Ruggiero, Edoardo Francini
Publikováno v:
Scopus-Elsevier
Background The authors investigated the incidence of and risk factors for osteonecrosis of the jaw (ONJ) in patients with metastases to the bone who received the bisphosphonate agent zoledronic acid (ZOL) and chemotherapy combined with the antiangiog
Autor:
Giorgio Chiriacò, Antonio Manganelli, Roberto Petrioli, A.I. Fiaschi, Roberto Ponchietti, Edoardo Francini, Alessandra Pascucci, G. De Rubertis, Guido Francini, Gianluca Bargagli, G. Barbanti, Raffaele Conca
Publikováno v:
British Journal of Cancer
The results of two large randomised trials have provided substantial support in favour of the role of chemotherapy in the treatment of castrate-resistant prostate cancer (CRPC) by demonstrating that docetaxel (D) and prednisone (P) improve survival i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a0db435d50184e2e3d73d93ca08670
http://hdl.handle.net/11365/23855
http://hdl.handle.net/11365/23855
Autor:
Giandomenico Roviello, Roberto Ponchietti, Antonio Manganelli, G Marzocca, Antonella Licchetta, Salvatora Tindara Miano, Filippo Francini, Raffaele Conca, Alessandra Pascucci, Giorgio Chiriacò, Edoardo Francini, Gianluca Bargagli, Ignazio Martellucci, Vinno Savelli, Roberto Petrioli
Publikováno v:
Prostate Cancer
Prostate Cancer, Vol 2011 (2011)
Prostate Cancer, Vol 2011 (2011)
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D.Methods. Treatment consisted of D 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225b458b13296cade0e08b885516aeff
http://hdl.handle.net/11365/22757
http://hdl.handle.net/11365/22757